LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Company News/Bernie Haffey Joins Accelus Board of Directors
Company News

Bernie Haffey Joins Accelus Board of Directors

March 11, 2024 2 min read Premium comments

Advertisement

Bernie Haffey Joins Accelus Board of Directors
Bernie Haffey / Courtesy of Accelus Corporation
#accelusSecondary#berniehaffey

Bernie Haffey, a veteran executive and corporate leader, has joined the Board of Directors of Palm Beach Gardens, Florida-based Accelus Corporation. For over 20 years, Haffey has been CEO of his own firm, Haffey and Co., known for its High-Performance Management System (HPMS), which has transformed performance at more than 50 businesses and organizations.

Prior to launching Haffey & Co., Haffey was president and CEO of two venture-backed start-ups, Nexis Vision, Inc., and NDO Surgical, Inc., both of which achieved structured exits under his leadership. Additionally, he held positions as executive vice president and chief commercial officer at both Summit Technology, Inc., and IntraLase Corp. Under Haffey’s leadership, these companies achieved revenues exceeding $100 million and exits of $1 billion and $800 million, respectively.

Haffey serves on the Board of Directors of On Target Laboratories, Inc. and Medevise Consulting and previously served on the boards of WaveTec Vision, Inc., acquired by Alcon Labs, and Ocular Therapeutix, Inc. Haffey holds a B.A. from Colgate University and an M.B.A. from Cornell University.

Haffey joins Accelus at a particularly opportune time. Not only has the company recently hired a new CEO, but it also closed on new financing. Among the key products in Accelus’s portfolio are:

  • Adaptive GeometryTM technology, used in its flagship product, the FlareHawk® Interbody Fusion System
  • Toro®-L biplanar-expandable lateral implant
  • LineSider® Spinal System, a posterior screw system that gives surgeons the ability to tailor their surgical construct to each patient’s pathology
  • BioNest® allograft bone matrix, a 100% human allograft demineralized bone matrix designed for ease of flow for post-pack graft delivery into the surgical site.

Haffey, who will be bringing his HPMS system into Accelus, told OTW, “I believe that HPMS firmly lays the groundwork for cultivating a culture of excellence. This is achieved through the establishment of shared values and ensuring organizational alignment.”

“Our approach is distinctive because of our focus on the Vital Few, which sharpens Accelus’s ability to execute with excellence. This focus, when integrated with our Breakthrough Process, positions Accelus uniquely by executing through a management system that is deeply rooted in proven quality principles.”

“As I step into this role, my initial focus will be on acquiring a profound understanding of our technology, customers, markets, and competition. This foundational knowledge is crucial for me to effectively support and lead the company forward.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy